Conference Coverage

Obesity may attenuate anti-TNF response in psoriatic arthritis


 

References

DANBIO is supported by unrestricted grants from Abbott, Pfizer, MSD, Bristol-Myers Squibb, Roche, and UCB-Nordic. The sponsors have had no influence on data collection, analysis, or publication. ICEBIO is part of the electronic medical record system held by the University of Reykjavik and receives no industrial funding. Ms. Højgaard has received speaking fees from Celgene and UCB not related to this work.

Pages

Recommended Reading

Severe psoriasis, kidney disease linked
MDedge Dermatology
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
MDedge Dermatology
How to beat apremilast-induced diarrhea
MDedge Dermatology
Psoriasis tied to abdominal aortic aneurysm in nationwide study
MDedge Dermatology
Effective psoriasis therapy may reduce coronary plaque burden
MDedge Dermatology
Brodalumab effective for rare, severe types of psoriasis
MDedge Dermatology
Serious infections are increasing among psoriasis inpatients
MDedge Dermatology
Full resolution of psoriasis in half of ixekizumab patients
MDedge Dermatology
TNF blocker safety may differ in RA and psoriasis patients
MDedge Dermatology
TB still a risk in psoriasis patients taking TNF blockers
MDedge Dermatology